Department of Women's and Children's Health, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, England.
St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, England.
JAMA Ophthalmol. 2020 Apr 1;138(4):395-403. doi: 10.1001/jamaophthalmol.2020.0173.
The 2-year ophthalmic sequelae of Ebola virus disease (EVD) in survivors of the 2013 to 2016 epidemic is unknown and may have public health implications for future outbreaks.
To assess the potential for uveitis recurrence, the behavior of dark without pressure, and visual outcomes in a cohort of Sierra Leonean survivors of EVD 2 years following the 2013 to 2016 Ebola epidemic.
DESIGN, SETTING, AND PARTICIPANTS: Prospective, 1-year observational cohort study performed between 2016 and 2017 at 34 Military Hospital, Freetown, Sierra Leone. Participants included survivors of EVD who reported ocular symptoms since Ebola treatment unit discharge and were participants of a previous case-control study. Participants were invited for ophthalmic reexamination and finger-prick blood sampling for immunoglobulin G (IgG) to Toxoplasma gondii and HIV.
Ebola virus disease.
Primary outcome measure: comparative ultra-widefield retinal imaging. Secondary outcome measures: visual acuity and detection of IgG to T gondii and HIV.
Of 57 survivors of EVD who underwent repeated ophthalmic evaluation, 37 were women (64.9%). Mean (SD) age was 31.9 (11.1) years. Median interval between first and last examination was 370 days (interquartile range [IQR], 365-397.5 days), and median time from discharge to last examination was 779 days (IQR, 732-821 days). Fifteen eyes of 10 survivors (17.5%) had retinal lesions secondary to EVD. No new EVD-associated retinal lesions were observed. Two survivors (3.5%) developed new posterior uveitis resembling toxoplasmosis chorioretinitis and 41 (73%) were seropositive for T gondii IgG. Areas of dark without pressure were observed either confined to the perimeter of Ebola retinal lesions (n = 7) and non-Ebola lesions (n = 2), involving extensive retinal areas adjacent to Ebola retinal lesions (n = 4) and non-Ebola lesions (n = 2) or in isolation (n = 6). Both expansion and regression of areas of dark without pressure were observed over the study period. Best eye-presenting visual acuity had mild or no visual impairment in 55 survivors (96.4%) 2 years following discharge.
Vision was maintained in survivors of EVD 2 years following discharge. Evolving regions of dark without pressure may be associated with EVD retinal lesions and might suggest the presence of an ongoing intraretinal stimulus, which may be associated with infective etiology. Treatment strategies should account for the possibility of toxoplasmosis chorioretinitis recurrence within survivors of EVD.
埃博拉病毒病(EVD)幸存者 2 年后的眼科后遗症尚不清楚,这可能对未来的疫情爆发产生公共卫生影响。
评估 2013 年至 2016 年埃博拉疫情后塞拉利昂幸存者队列中葡萄膜炎复发、暗区无压力行为和视觉结局的可能性。
设计、地点和参与者:2016 年至 2017 年在塞拉利昂弗里敦 34 号军事医院进行的前瞻性、1 年观察性队列研究。参与者包括自埃博拉治疗单元出院以来出现眼部症状并参加过先前病例对照研究的 EVD 幸存者。邀请参与者进行眼科复查和指尖采血,以检测 IgG 对弓形体和 HIV。
埃博拉病毒病。
主要结局测量:比较超广角视网膜成像。次要结局测量:视力和 IgG 对弓形体和 HIV 的检测。
在接受重复眼科评估的 57 名 EVD 幸存者中,有 37 名女性(64.9%)。平均(SD)年龄为 31.9(11.1)岁。首次和末次检查之间的中位间隔为 370 天(四分位距[IQR],365-397.5 天),从出院到末次检查的中位时间为 779 天(IQR,732-821 天)。10 名幸存者中有 15 只眼(17.5%)有埃博拉病毒病引起的视网膜病变。未发现新的与 EVD 相关的视网膜病变。2 名幸存者(3.5%)出现新的类似于弓形体脉络膜视网膜炎的后葡萄膜炎,41 名幸存者(73%)IgG 对弓形体呈阳性。暗区无压力的区域要么局限于埃博拉视网膜病变(n=7)和非埃博拉病变(n=2)的周边,要么涉及与埃博拉视网膜病变(n=4)和非埃博拉病变(n=2)相邻的广泛视网膜区域,要么单独存在(n=6)。在研究期间,暗区无压力的区域既出现了扩张也出现了缩小。出院后 2 年,55 名幸存者(96.4%)的最佳视力表现出轻度或无视力损害。
EVD 幸存者的视力在出院后 2 年内得到维持。不断变化的暗区无压力区域可能与 EVD 视网膜病变有关,可能提示存在持续的视网膜内刺激,这可能与感染病因有关。治疗策略应考虑到 EVD 幸存者中弓形体脉络膜视网膜炎复发的可能性。